MPDL3280A (also known as anti-PDL1) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1. MPDL3280A is designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.
This antibody treatment is used in the OAK trial. Patient with lung cancer who have failed certain treatment s before, may be eligible. Patient either receive MPDL3280A or standard of care chemotherapy docetaxel (Taxotere) (A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK) (For more information on clinicaltrials.gov click here)
For more information contact Irene, clinical research coordinator at 562-590-0345